

Stefanie Schulz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2535374/stefanie-schulz-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

7,146
citations

44
h-index

83
g-index

135
ext. papers

8,123
ext. citations

7.4
avg, IF

5.02
L-index

#	Paper	IF	Citations
125	Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021 , 10, e021418	6	0
124	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1121-1129	16.2	5
123	Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2021 , 10, e020165	6	1
122	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010565	6	1
121	Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021 ,	4	2
120	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1857-1866	5	2
119	Resultado del tratamiento percutáneo de la reestenosis de stents farmacoactivos: ¿depende de si el stent tenía o no recubrimiento polimérico?. <i>Revista Espanola De Cardiologia</i> , 2020 , 73, 225-231	1.5	
118	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 348-362	7	8
117	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2238-2247	5	11
116	Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020 , 142, 2329-2337	16.7	14
115	Do outcomes following intervention for drug-eluting stent restenosis depend on whether the restenosed stent was polymer-free or polymer-coated?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 225-231	0.7	
114	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019 , 381, 1524-1534	59.2	327
113	Sex differences in the outcome after percutaneous coronary intervention - A propensity matching analysis. <i>Cardiovascular Revascularization Medicine</i> , 2019 , 20, 101-107	1.6	12
112	Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1973-1982	15.1	32
111	Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 92, 1239-1246	2.7	1
110	Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006074	6	9
109	Increased bleeding risk during percutaneous coronary interventions by arterial hypertension. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, 184-90	2.7	3

108	Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). <i>Thrombosis Research</i> , 2016 , 137, 72-78	8.2	5
107	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. <i>EuroIntervention</i> , 2016 , 11, 1372-9	3.1	52
106	Motivations for and barriers to choosing an interventional cardiology career path: results from the EAPCI Women Committee worldwide survey. <i>EuroIntervention</i> , 2016 , 12, 53-9	3.1	27
105	Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. <i>EuroIntervention</i> , 2016 , 11, e1275-82	3.1	
104	Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2015 , 36, 3202-10	9.5	59
103	Reply: Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention: Results of the ISAR-ASPI Registry. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2154	15.1	
102	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 877-84	5	62
101	The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. <i>Thrombosis Research</i> , 2015 , 136, 87-93	8.2	20
100	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1619-1629	15.1	331
99	Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 35-42	5.1	16
98	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). <i>BioMed Research International</i> , 2015 , 2015, 798486	3	11
97	Assessing the benefit of vascular closure devices after femoral artery puncture--reply. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 855-6	27.4	2
96	Predictors of antiplatelet response to prasugrel during maintenance treatment. <i>Platelets</i> , 2015 , 26, 53-63	3.6	16
95	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015 , 36, 1252-63	9.5	296
94	Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 91-100	3.3	73
93	Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 29-36	5	37
92	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. <i>American Heart Journal</i> , 2014 , 167, 459-465 e1	4.9	15
91	Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. <i>Clinical Cardiology</i> , 2014 , 37, 270-6	3.3	15

90	Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 863-71	15.1	77
89	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2014 , 35, 2285-94	9.5	79
88	A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 342-51	7	34
87	Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 1190-7	7	22
86	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 1041-9	7	13
85	Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. <i>American Heart Journal</i> , 2014 , 168, 862-8.e1	4.9	6
84	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. <i>Catheterization and Cardiovascular Interventions</i> , 2014 , 83, 182-9	2.7	21
83	Correlates of poor outcome among patients with bleeding after coronary interventions. <i>Coronary Artery Disease</i> , 2014 , 25, 456-62	1.4	4
82	Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1981-7	27.4	121
81	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. <i>Cardiovascular Revascularization Medicine</i> , 2014 , 15, 69-75	1.6	10
80	Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. <i>Clinical Research in Cardiology</i> , 2014 , 103, 49-56	6.1	10
79	Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. <i>EuroIntervention</i> , 2014 , 10, 83-9	3.1	2
78	Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial. <i>EuroIntervention</i> , 2014 , 10, 198-203	3.1	5
77	Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2075-82	15.1	61
76	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. <i>Lancet, The</i> , 2013 , 381, 461-7	40	277
75	Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2013 , 165, 537-43	4.9	12
74	Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 1267-74	5	216
73	Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. <i>American Heart Journal</i> , 2013 , 166, 534-40	4.9	34

72	Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. <i>International Journal of Cardiology</i> , 2013 , 167, 575-84	3.2	128
71	Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. <i>American Heart Journal</i> , 2013 , 165, 80-6	4.9	33
70	Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 354-61	6	44
69	Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non ST-segment elevation myocardial infarction. <i>Journal of Interventional Cardiology</i> , 2013 , 26, 623-9	1.8	2
68	Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, E769-76	2.7	13
67	High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring. <i>Platelets</i> , 2013 , 24, 500-2	3.6	2
66	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 517-24	7	12
65	One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. <i>EuroIntervention</i> , 2013 , 9, 430-6	3.1	20
64	Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. <i>International Journal of Cardiology</i> , 2013 , 167, 575-584	3.2	83
63	The impact of smoking on the antiplatelet action of clopidogrel in non-ST-elevation myocardial infarction patients: results from the ISAR-REACT 4 platelet substudy. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 2199-202	15.4	7
62	Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 369-77	15.1	37
61	Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 769-74	7	9
60	Prognostic value of uric acid in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2012 , 109, 1260-5	3	53
59	No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 82-8, S1-2	6	34
58	Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 705-12	6	22
57	Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Circulation</i> , 2012 , 125, 1424-31	16.7	165
56	Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1325-31	15.1	116
55	Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2011 , 365, 1980-9	59.2	230

54	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. <i>American Heart Journal</i> , 2011 , 161, 68-75	4.9	84
53	Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. <i>Clinica Chimica Acta</i> , 2011 , 412, 1350-6	6.2	16
52	Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. <i>Thrombosis Research</i> , 2011 , 127, 119-21	8.2	13
51	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. <i>Lancet, The</i> , 2011 , 378, 1071-8	4.0	129
50	Sensitive troponin and N-terminal pro-brain natriuretic peptide in stable angina. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 1054-62	4.6	11
49	High-sensitivity troponin T level and angiographic severity of coronary artery disease. <i>American Journal of Cardiology</i> , 2011 , 108, 639-43	3	42
48	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. <i>Clinical Research in Cardiology</i> , 2011 , 100, 579-85	6.1	3
47	Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. <i>Clinical Research in Cardiology</i> , 2011 , 100, 691-9	6.1	7
46	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. <i>Catheterization and Cardiovascular Interventions</i> , 2011 , 77, 494-501	2.7	12
45	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. <i>European Heart Journal</i> , 2011 , 32, 1605-13	9.5	158
44	Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. <i>Circulation</i> , 2011 , 124, 624-32	16.7	99
43	Selective Qeel syndrome?. <i>Europace</i> , 2011 , 13, 143; author reply 143-4	3.9	2
42	Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. <i>Circulation: Cardiovascular Interventions</i> , 2010 , 3, 408-13	6	105
41	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. <i>European Heart Journal</i> , 2010 , 31, 582-7	9.5	48
40	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010 , 31, 2482-91	9.5	69
39	Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. <i>European Heart Journal</i> , 2010 , 31, 1205-11	9.5	64
38	A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 558-65	15.1	48
37	Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2710-6	15.1	162

36	2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2536-43	15.1	102
35	Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 317-8	15.1	169
34	Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. <i>American Heart Journal</i> , 2010 , 160, 355-61	4.9	16
33	ISAR--a story of trials with impact on practice. <i>Circulation Journal</i> , 2010 , 74, 1771-8	2.9	6
32	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 626-32	7	23
31	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Heart and Vessels</i> , 2010 , 25, 27-34	2.1	18
30	Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. <i>Heart and Vessels</i> , 2010 , 25, 294-8	2.1	6
29	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. <i>Clinical Research in Cardiology</i> , 2010 , 99, 13-9	6.1	8
28	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2010 , 99, 345-57	6.1	29
27	One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. <i>Clinical Research in Cardiology</i> , 2010 , 99, 795-802	6.1	20
26	Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. <i>American Journal of Cardiology</i> , 2010 , 105, 163-7	3	22
25	Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. <i>American Journal of Cardiology</i> , 2010 , 106, 1212-7	3	42
24	Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 250-6	15.4	274
23	Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. <i>Circulation</i> , 2009 , 119, 1933-40	16.7	249
22	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. <i>European Heart Journal</i> , 2009 , 30, 2714-21	9.5	199
21	Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2009 , 2, 430-7	6	39
20	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>European Heart Journal</i> , 2009 , 30, 2441-9	9.5	180
19	Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. <i>American Journal of Kidney Diseases</i> , 2009 , 54, 830-9	7.4	23

18	Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 1142-8	5	17
17	Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. <i>Clinica Chimica Acta</i> , 2009 , 409, 46-51	6.2	6
16	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. <i>American Heart Journal</i> , 2009 , 157, 620-4.e2	4.9	79
15	Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1760-8	15.1	153
14	Patterns of presentation and outcomes of patients with acute coronary syndromes. <i>Cardiology</i> , 2009 , 113, 198-206	1.6	24
13	Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Clinical Science</i> , 2009 , 116, 651-8	6.5	18
12	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. <i>European Heart Journal</i> , 2009 , 30, 290-6	9.5	44
11	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. <i>European Heart Journal</i> , 2009 , 30, 923-31	9.5	104
10	Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. <i>Journal of Internal Medicine</i> , 2008 , 264, 472-80	10.8	70
9	Tratamiento de la reestenosis de stents liberadores de paclitaxel mediante implantaci3n de stents liberadores de sirolimus. Resultados angiogr3ficos y cl3nicos. <i>Revista Espanola De Cardiologia</i> , 2008 , 61, 1134-1139	1.5	7
8	Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 512-7	15.1	58
7	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. <i>European Heart Journal</i> , 2008 , 29, 1975-82	9.5	158
6	Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. <i>Cardiology</i> , 2008 , 111, 247-53	1.6	10
5	Arylsulfatase G, a novel lysosomal sulfatase. <i>Journal of Biological Chemistry</i> , 2008 , 283, 11388-95	5.4	35
4	Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. <i>New England Journal of Medicine</i> , 2008 , 359, 688-96	59.2	287
3	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. <i>Clinical Research in Cardiology</i> , 2008 , 97, 160-8	6.1	11
2	Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 852-857	7	47
1	Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 852-7	7	28

